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Editorial on the Research Topic
Advanced Therapies for Cardiac Regeneration
Cardiovascular diseases (CVDs) are the leading cause of death worldwide, accounting for ∼18
million deaths annually (WHO data). The term CVD gathers a group of different disorders
involving the heart, its constituent structures, and the blood vessels. Among CVDs, coronary heart
disease and stroke are responsible for four out of five CVD-related deaths, and one third of these
deaths occur prematurely in people aged 70 or younger. The progressive or sudden obstruction
of the coronary arteries is responsible for the onset of myocardial infarction which initiates a
detrimental cascade of events finally leading to heart failure. More in detail, heart failure results
from the continuous remodeling of the scar tissue replacing the beating heart muscle in the
infarcted region, and represents a chronic condition in which the heart muscle progressively loses
its ability to pump enough blood to fulfill the needs of all the body’s compartments. Heart failure
thus represents the main cause of morbidity and mortality of myocardial infarcted patients in the
long term.Within this context, cardiac tissue engineering/regenerative medicine (TERM) strategies
could arise as cutting-edge therapies in the management of myocardial infarcted patients, opening
the way to the possibility to replace the damaged heart tissue and recover its functionality. Such an
approach could effectively represent a valid alternative to the gold standard heart transplantation,
encompassing all issues related to donor shortage and the need for life-long administration of
immunosuppressive therapies. Among other common cardiovascular diseases, we also recall valve
heart diseases and cardiomyopathies. It must be highlighted the strong associations existing
between different cardiovascular diseases, such as coronary heart disease and valvular heart disease,
cardiomyopathy and heart failure. This observation indicates that a multiple regenerative medicine
approach, which considers different diseases, could be an effective strategy in the management of
CVDs. The Research Topic “Advanced Therapies for Cardiac Regeneration” aims at presenting
a series of articles summarizing the latest research updates on cardiac TERM approaches which
combine cells, biomaterials, hydrogels, tissue engineered scaffolds/patches and physico-chemical
stimuli to achieve the ultimate goal of regenerating the injured heart tissue. The issue is comprised
of 19 peer-reviewed manuscripts (nine reviews, two perspectives, seven original research articles,
and one Brief Research Report) derived from the many fields involved in the topic, namely
(bio)materials science and engineering, biology, biotechnology, and biomedical engineering.
To better contextualize the Research Topic, the review by Montero et al. presents an in-depth
overview of the specific characteristics of the myocardium that determine the needs and
requirements cardiac TERM has to meet, with particular emphasis on heart tissue components,
architecture and biophysical properties. The authors also briefly revise the key components
required to design new cardiac TERM approaches, namely cells, materials, maturation stimuli,
and scaffold fabrication techniques. Given the central role of biomaterials in the establishment
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of cardiac TERM therapies, Bar and Cohen focus their review
on the current application of biomaterials in the field of cardiac
regeneration, mainly discussing their use as forming materials
for nano-carriers and matrices for cardiac regeneration induced
by biomolecule release, injectable hydrogels for cell delivery, and
cardiac patches. Further and more detailed insight on the use of
specific biomaterials in cardiac TERM are provided by Cattelan
et al. and Gonzalez De Torre et al., with particular emphasis
on their application as hydrogel constituents. Being three-
dimensional highly hydrated networks showing mechanical
properties similar to soft tissues, hydrogels hold great promise in
cardiac TERM. Cattelan et al. elucidate the promising properties
of alginate in cardiac regeneration strategies and the outcomes
of clinical trials in which this material has been tested to treat
myocardial infarcted patients. An additional demonstration of
the suitability of this material for cardiac TERM is provided by
Bloise et al. who develop alginate hydrogels for the controlled
release of immunomodulatory and reparative cytokines (anti-
inflammatory interleukins 4/6/13 and colony-stimulating factor)
to direct immune cell fate and control the wound healing process
in the ischemic heart. The therapeutic ability of the proposed
treatment has been proved in rat models by macrophage
polarization toward healing and the improved global cardiac
functionality. Differently, Gonzalez De Torre et al. discuss on
the potential of elastin-based biomaterials as constituents of
hydrogel scaffolds, injectable systems, or complex devices (e.g.,
heart valves, stents) to treat CVD-affected patients. In this
regard, Fernàndez-Colino et al. investigate the use of elastin-like
recombinamers as forming materials of small caliber compliant
vascular grafts. The authors describe material processing
into macroporous three-dimensional structures favoring cell
homing, extracellular matrix (ECM) deposition and endothelium
development, while exhibiting non-thrombogenicity and elastic
properties mimicking the native elastin. Graft textile components
are finely designed to confer proper suture retention, long-
term structural stability, burst strength and compliance. The
proper selection of the biomaterials used as constituents of
cardiac scaffolds/patches/devices or hydrogels thus represents
the first step toward the engineering of successful regenerative
strategies for the management of CVD-affected patients. Indeed,
biomaterials strongly affect the possibility to provide the resulting
devices with proper biological signals and physical stimuli to
achieve the final goal of recovering the initial organ/tissue
functionality. In this regard, Belviso et al. report on the potential
of decellularized human skin as scaffold to restore the native
ECM which plays a pivotal role in guiding heart compliance,
cardiomyocyte maturation, and function. The authors argue that
a dermal matrix could effectively represent a viable alternative
biological scaffold in cardiac TERM, with the key advantages
of being autologous, easily accessible, and cost-effective. On
the other hand, decellularized organ-derived ECM (dECM) can
also be exploited to design hydrogels, thus combining the ECM
characteristic pro-regenerative properties with the possibility to
shape the material according to specific requirements. Liguori et
al. investigate the differences among dECM hydrogels prepared
starting from cardiovascular tissues of different origin, namely
left ventricle, mitral valve, and aorta. The authors demonstrate
that the source of dECM plays a pivotal role in determining cell
differentiation and vascular network formation, because of the
different molecular and biomechanical cues provided to cells.
For instance, ventricular dECM hydrogels exhibit more robust
vascular network formation, while aorta-derived dECM drives
adipose-derived stromal cell differentiation toward a myogenic
phenotype in the absence of TGF-β1 supplement to the culture
medium. The readers can also find a thorough survey on the use
of decellularized cardiac ECMas biomaterial for cardiac TERM in
the review by Maghin et al. Besides the physical stimuli provided
by the designed cell-culture platforms through their architecture
and their mechanical properties, the possibility to mechanically
stimulate cellularized constructs by mimicking the native milieu
also promotes the development and maturation of cardiac tissue
analogs, as described by Massai et al. The authors develop an
automated bioreactor platform for tuneable cyclic stretch of
cellularized samples coupled with a specific set-up for the in situ
monitoring of the mechanical response of in vitro engineered
cardiac tissues. Another key form of stimulus playing a central
role in cardiac regeneration is represented by biochemical cues,
as thoroughly surveyed by Cassani et al. Particularly, the authors
mainly gather their attention on the crucial need of specific
carriers (e.g., nanoparticles) to deliver such biochemical cues,
which would ensure an efficient delivery of the therapeutic
cargo, inhibit its metabolic inactivation, and avoid potential side
effects. According to a different approach, proper biochemical
stimuli driving cardiac repair and regeneration can be also
applied by cell-secreted soluble factors. The literature review
by Maghin et al. reports on the therapeutic profiling of stem
cell secretome, with regard to the cardio-active ability of
cell-released extracellular vesicles, including exosomes carrying
cardioprotective and regenerative RNA molecules. An in-depth
analysis of the potential and themechanisms of action ofmiRNAs
as mediators of cardioprotection is provided by Nazari-Shafti
et al. The authors highlight the crucial need to identify all
miRNAs involved in cardioprotection and remodeling, as well
as their composition and exact mechanism of action in view
of their application in clinical practice. A class of miRNAs
has also been reported to drive the direct reprogramming of
fibroblasts into cardiomyocyte-like cells. In the perspective of
a clinical translation of this approach, Paoletti et al. test the
capability of miRcombo (i.e., a combination of four microRNA
mimics) to guide the direct reprogramming of adult human
cardiac fibroblasts into induced cardiomyocytes, as previously
observed with murine fibroblasts. Other repair and regenerative
strategies currently explored in literature target different aspects
of the cascade initiated by myocardial insults. For instance, Seclì
et al. concentrate on the different role exerted by chaperone
proteins in the healthy and injured heart. In detail, in the
healthy heart chaperone proteins contribute to the regulation of
myocardial physiology, while under stress conditions or during
cell damage events, they are secreted by myocardial cells and
induce inflammation and cardiomyocyte apoptosis. Blocking
chaperone activity has been already demonstrated to produce
beneficial effects on heart function in preclinical models. Hence,
combining the release of specific antibodies blocking extracellular
chaperones with TERM approaches may represent a future
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innovation to treat infarcted patients. Differently, Bigotti et al.
discuss the possible exploitation of agrin as mediator of cardiac
regeneration. Recently published works have demonstrated that
agrin can promote heart regeneration in murine models through
cardiomyocyte de-differentiation and proliferation.Moving from
these data, the authors survey the currently available literature
on this topic, and critically discuss on the potential clinical
translation of agrin-based therapies.
Last but not least, a new chapter in the TERM field has
been opened over the last two decades with the discovery of
induced pluripotent stem cells (iPSCs). These cells offer the
advantage of being of autologous origin, while retaining the
proper characteristics of embryonic stem cells, thus completely
overcoming both ethical issues and rejection risks. Mazzola
and Di Pasquale provide an overview on the differentiation
potential of iPSCs toward cardiomyocytes and their application
in cell-based therapies, highlighting the typical drawbacks of
such approaches in terms of poor cell retention and risks of
occurrence of adverse effects (e.g., arrhythmias). A possible
route to overcome these issues consists in combining the use
of iPSCs with bioengineering technologies which can retain
cells in the therapeutic target while favoring their phenotypical
maturation and integration in the host tissue. iPSCs can also
be successfully used as cell source in the establishment of
cardiac tissue models. In addition, their autologous origin can be
exploited to recapitulate in vitro human cardiac pathophysiology.
In this regard, Jelinkova et al. report the design of an in vitro
human model of the cardiac tissue of Duchenne muscular
dystrophy (DMD)-affected patients. DMD is a severe genetic
disorder associated with progressive dilated cardiomyopathy
which culminates with heart failure onset, finally leading to
patient death. The authors demonstrate that the designed cardiac
models effectively recapitulate DMD-induced functional defects
and cardiac wasting, thus offering a promising tool for a
better understanding of DMD-associated cardiomyopathy and
its treatment.
Finally, to complete our survey on the topic, Taghizadeh et
al. exhaustively review the different types of biomaterials applied
in the treatment of valvular heart diseases which represent
another CVD with high incidence in developed countries, and
in particular among the elderly. In the U.S. about 28,000 deaths
are due to heart valve disease every year, with approx. the
60% of deaths due to disorders involving the aortic valve (data
from the Centers for Disease Control and Prevention). Strict
requirements in terms of material physico-chemical properties
should also be fulfilled when vascular stents are engineered.
Learning from a recent FDA report dealing with the adverse
cardiac events and thrombosis observed at the 2-year follow-
up on the first FDA-approved bioresorbable vascular stents,
Pacharra et al. characterize a series of polyethylene glycol-
functionalized poly-L-lactide-co-ε-caprolactone copolymers as a
new generation of stent-forming materials, with improved cyto-
and hemo-compatibility. As an outcome of the research work, the
authors identify promising candidates for cardiovascular implant
fabrication, with the additional advantage of being suitable for an
easy translation of the synthesis procedure (a one-step synthesis
strategy) toward industrial practice.
The reader can easily appreciate from the brief summaries
of the contributions comprised in this issue that the addressed
Research Topic is broad in nature and represents a still open
question in the TERM field. The definition of regenerative
approaches to fight the detrimental consequences of CVDs
is still in its infancy. However, the cross-contamination
of new ideas coming from complementary but not
overlapping fields, as highlighted in the papers published
within this issue, will likely lead in the future to the
effective and successful repair and regeneration of injured
myocardial tissue.
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